SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 10)*

Solid Biosciences Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

(CUSIP Number)

Perceptive Advisors LLC
Alexander Rakitin, 51 Astor Place, 10th Floor
New York, NY, 10003
646-205-5345

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/30/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Perceptive Advisors LLC
2	Check the appropriate box if a member of a Group (See Instructions)

☐ (a)
☑ (b)

3 SEC use only

4 Source of funds (See Instructions)

AF

5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

☑

6 Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7 Sole Voting Power

0.00

8 Shared Voting Power

12,046,579.00

9 Sole Dispositive Power

0.00

10 Shared Dispositive Power

12,046,579.00

11 Aggregate amount beneficially owned by each reporting person

12,046,579.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

☐

13 Percent of class represented by amount in Row (11)

11.2 %

14 Type of Reporting Person (See Instructions)

IA

SCHEDULE 13D

CUSIP No.

1 Name of reporting person

Joseph Edelman

2 Check the appropriate box if a member of a Group (See Instructions)

☐ (a)
☑ (b)

3 SEC use only

4 Source of funds (See Instructions)

AF

5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

☐

6 Citizenship or place of organization

UNITED STATES

Number of

7 Sole Voting Power

Shares Beneficially Owned by Each Reporting Person With:		0.00
	8	Shared Voting Power 12,046,579.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 12,046,579.00

11	Aggregate amount beneficially owned by each reporting person 12,046,579.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐
13	Percent of class represented by amount in Row (11) 11.2 %
14	Type of Reporting Person (See Instructions) IN

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Perceptive Life Sciences Master Fund, Ltd.
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6	Citizenship or place of organization CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 11,973,472.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 11,973,472.00

11	Aggregate amount beneficially owned by each reporting person

	11,973,472.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐
13	Percent of class represented by amount in Row (11) 11.2 %
14	Type of Reporting Person (See Instructions) CO

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Perceptive Xontogeny Venture Fund, LP	
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)	
3	SEC use only	
4	Source of funds (See Instructions) WC	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐	
6	Citizenship or place of organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 73,107.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 73,107.00
11	Aggregate amount beneficially owned by each reporting person 73,107.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	
13	Percent of class represented by amount in Row (11) 0.1 %	
14	Type of Reporting Person (See Instructions) CO	

SCHEDULE 13D

Item 1. Security and Issuer

(a) Title of Class of Securities:

Common Stock, $0.001 par value per share

(b) Name of Issuer:

Solid Biosciences Inc.

(c) Address of Issuer's Principal Executive Offices:

500 Rutherford Avenue, Third Floor, Charlestown, MASSACHUSETTS , 02129.

Item 5. Interest in Securities of the Issuer

(a) The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentages set forth in row 13 are based on a total of 107,365,171 shares of Common Stock, consisting of (i) 107,225,238 shares of Common Stock outstanding as of August 4, 2026, as disclosed by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026, and (ii) 139,933 shares of Common Stock issuable upon exercise of vested stock options held by Adam Stone ("Mr. Stone"), the Chief Investment Officer of Perceptive Advisors LLC ("Perceptive Advisors"), described below.

(b) The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference. Neither Perceptive Advisors nor Joseph Edelman ("Mr. Edelman") directly holds any Common Stock or pre-funded warrants. Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund") directly holds 11,833,539 shares of Common Stock and 8,912,655 pre-funded warrants (the "Pre-Funded Warrants") immediately exercisable for shares of Common Stock at an exercise price of $0.001 per share, subject to the Beneficial Ownership Limitation (as defined below). The terms of the Pre-Funded Warrants provide that the Pre-Funded Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Reporting Persons to exercise any portion of the Pre-Funded Warrants. Perceptive Xontogeny Venture Fund, LP (the "Venture Fund") directly holds 73,107 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and the Venture Fund. Mr. Edelman is the managing member of Perceptive Advisors. Adam Stone, the Chief Investment Officer of Perceptive Advisors, holds stock options for a total of 217,433 shares of Common Stock, of which 139,933 are currently exercisable, or exercisable within 60 days. The Master Fund has the right to receive the director compensation provided in respect of Mr. Stone's board service through a partial management fee offset.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Perceptive Advisors LLC

Signature: /s/ Joseph Edelman
Name/Title: Joseph Edelman, Managing Member
Date: 08/14/2026

Joseph Edelman

Signature: /s/ Joseph Edelman
Name/Title: Joseph Edelman
Date: 08/14/2026

Perceptive Life Sciences Master Fund, Ltd.

Signature: /s/ Joseph Edelman
Name/Title: Joseph Edelman, Managing Member
Date: 08/14/2026

Perceptive Xontogeny Venture Fund, LP

Signature: /s/ Joseph Edelman
Name/Title: Joseph Edelman, Managing Member
Date: 08/14/2026